Fairvalue-Calculator Fairvalue-Calculator
EN DE

Boryung Corporation (003850) Fair Value & Analysis

Healthcare · KR · Market cap 743B KRW

Price8,280 KRW
Fair Value12,940 KRW
Upside+56.3%
Quality95/100
Evidence: High Range 9,705 KRW – 16,175 KRW

Fair value as of: Jun 25, 2026

✦ Find undervalued quality stocks — 34,000+ analysed Find stocks →

Analysis

Boryung Corporation (003850) currently trades at 8,280 KRW, while our model-based Fair Value estimate is 12,940 KRW — implying the stock looks roughly 56.3% undervalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: high) — always confirm before acting.

About the company

Boryung Corporation engages in the manufacture and sale of pharmaceutical products in South Korea and internationally. It offers prescription drugs for hypertension, dyslipidemia, and diabetes drugs. The company was formerly known as Boryung Pharmaceutical Co., Ltd. and changed its name to Boryung Corporation in March 2022. Boryung Corporation was founded in 1957 and is headquartered in Seoul, South Korea.

Open the full interactive analysis →

Similar stocks

Takeda Pharmaceutical Company (TAKP34) +1827% Jiangsu Hengrui Pharmaceuticals Co (600276) -43% Sun Pharmaceutical Industries Limited (SUNPHARMA) -49% Zoetis Inc (Z1TS34) -24% Hansoh Pharmaceutical Group (3692) -18% United Therapeutics Corporation (U2TH34) -6%

Frequently asked questions

Is Boryung Corporation (003850) undervalued?
As of Jun 25, 2026, our model estimates a fair value of 12,940 KRW versus a price of 8,280 KRW — about +56% (undervalued). Model-based estimate, not financial advice.
What is the fair value of 003850?
Our 21-model fair value for Boryung Corporation is 12,940 KRW (as of Jun 25, 2026), built from audited fundamentals. The current price is 8,280 KRW.
What is the quality score of 003850?
Boryung Corporation has a Quality Score of 95/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.